Four Patterns in End-of-Life Decline? - Scorecard - MDSpire

Four Patterns in End-of-Life Decline?

International cohort study found physical function declined most rapidly before mortality, while socioeconomic status was associated with more favorable multidomain trajectories.

  • By

  • Andrea Surnit

  • July 21, 2026

  • 4 min

Share

Clinical Scorecard: Four Patterns in End-of-Life Decline?

At a Glance

CategoryDetail
ConditionEnd-of-Life Decline
Key MechanismsDeclines in physical, cognitive, and psychological functioning during the final decade of life.
Target PopulationAdults aged 45 years or older from 17 countries.
Care SettingLongitudinal analysis of health data.

Key Highlights

  • Decedents experienced steeper declines in physical, cognitive, and psychological functioning compared to survivors.
  • Physical functioning showed the greatest deterioration, especially as mortality approached.
  • Four distinct patterns of decline were identified among decedents.
  • Higher socioeconomic status was associated with lower odds of unfavorable decline trajectories.
  • Educational attainment had a stronger association with favorable trajectories than household income.

Guideline-Based Recommendations

Diagnosis

  • Early screening to identify overall functional impairment.

Management

  • Strategies to reduce accelerated functional decline should start before old age.

Monitoring & Follow-up

  • Identifying co-decline patterns may inform targeted strategies.

Risks

  • Socioeconomic status may increase the likelihood of unfavorable multidomain patterns of decline.

Patient & Prescribing Data

Adults aged 45 years or older.

Focus on promoting healthy longevity and reducing end-of-life health inequalities.

Clinical Best Practices

  • Conduct regular assessments of physical, cognitive, and psychological functioning.
  • Implement interventions tailored to socioeconomically disadvantaged groups.

Related Resources & Content

Original Source(s)

Four Patterns in End-of-Life Decline?

  • by Andrea Surnit

  • July 21, 2026

Related Content

FDA Approves First Oral PCSK9 Inhibitor

Merck reported placebo-adjusted LDL-C reductions of 56% and 59% at week 24 in two phase 3 CORALreef trials supporting the approval.

Effect of Socioeconomic Status on SGLT2 Initiation in Heart Failure

A nationwide German claims analysis found lower initiation of guideline-recommended sodium-glucose cotransporter-2 inhibitors among women and patients living in lower-income municipalities.

Prolonged Sleep Restriction May Increase Body Weight

In a pooled analysis of two randomized crossover trials, reducing nightly sleep by about 1.5 hours for 6 weeks was associated with modest increases in body weight and waist circumference without measurable changes in body composition.